$82.96
2.02% today
Nasdaq, Dec 03, 09:17 pm CET
ISIN
US4622221004
Symbol
IONS

Ionis Pharmaceuticals, Inc. Stock price

$81.31
+7.66 10.40% 1M
+47.20 138.38% 6M
+46.35 132.58% YTD
+45.21 125.24% 1Y
+40.99 101.66% 3Y
+30.00 58.47% 5Y
+20.61 33.95% 10Y
+76.03 1,439.96% 20Y
Nasdaq, Closing price Tue, Dec 02 2025
-0.68 0.83%
ISIN
US4622221004
Symbol
IONS
Industry

New AI Insights on Ionis Pharmaceuticals, Inc. Insights AI Insights on Ionis Pharmaceuticals, Inc.

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
$13.2b
Enterprise Value
$12.2b
Net debt
positive
Cash
$2.2b
Shares outstanding
161.1m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
13.6 | 14.6
EV/Sales
12.6 | 13.5
EV/FCF
negative
P/B
21.3
Financial Health
Equity Ratio
19.6%
Return on Equity
-77.2%
ROCE
-13.1%
ROIC
-40.7%
Debt/Equity
2.0
Financials (TTM | estimate)
Revenue
$967.0m | $902.3m
EBITDA
$-274.3m | $-372.9m
EBIT
$-278.0m | $-413.1m
Net Income
$-256.3m | $-380.1m
Free Cash Flow
$-302.7m
Growth (TTM | estimate)
Revenue
20.4% | 28.0%
EBITDA
21.7% | 19.5%
EBIT
24.9% | 13.0%
Net Income
28.6% | 16.3%
Free Cash Flow
18.4%
Margin (TTM | estimate)
Gross
98.8%
EBITDA
-28.4% | -41.3%
EBIT
-28.8%
Net
-26.5% | -42.1%
Free Cash Flow
-31.3%
More
EPS
$-1.6
FCF per Share
$-1.9
Short interest
11.6%
Employees
1k
Rev per Employee
$660.0k
Show more

Is Ionis Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,097 stocks worldwide.

Ionis Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

31 Analysts have issued a Ionis Pharmaceuticals, Inc. forecast:

24x Buy
77%
7x Hold
23%

Analyst Opinions

31 Analysts have issued a Ionis Pharmaceuticals, Inc. forecast:

Buy
77%
Hold
23%

Financial data from Ionis Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
967 967
20% 20%
100%
- Direct Costs 12 12
13% 13%
1%
955 955
21% 21%
99%
- Selling and Administrative Expenses 352 352
42% 42%
36%
- Research and Development Expense 881 881
3% 3%
91%
-274 -274
22% 22%
-28%
- Depreciation and Amortization 3.78 3.78
81% 81%
0%
EBIT (Operating Income) EBIT -278 -278
25% 25%
-29%
Net Profit -256 -256
29% 29%
-27%

In millions USD.

Don't miss a Thing! We will send you all news about Ionis Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ionis Pharmaceuticals, Inc. Stock News

Neutral
Business Wire
one day ago
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to zilganersen for the treatment of Alexander disease (AxD), a rare, progressive and often fatal neurological condition. Over time, it can lead to loss of mobility and independence, along with difficulties wal...
Neutral
Business Wire
2 days ago
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to olezarsen as an adjunct to diet to reduce triglyceride (TG) levels in adults with severe hypertriglyceridemia (sHTG) (TG greater than or equal to 500 mg/dL). Breakthrough Therapy designation is intended to ...
Neutral
Seeking Alpha
15 days ago
Ionis Pharmaceuticals, Inc. ( IONS ) Jefferies London Healthcare Conference 2025 November 18, 2025 8:30 AM EST Company Participants Brett Monia - Founder, CEO & Director Conference Call Participants Akash Tewari - Jefferies LLC, Research Division Presentation Akash Tewari Jefferies LLC, Research Division Good afternoon. It's hard to check sometimes.
More Ionis Pharmaceuticals, Inc. News

Company Profile

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The Akcea Therapeutics segment develops and commercializes drugs for cardiometabolic diseases. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli and Brett P. Monia in 1989 and is headquartered in Carlsbad, CA.

Head office United States
CEO Brett Monia
Employees 1,069
Founded 1989
Website www.ionis.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today